Qi Yiming, Ding Hongke, Huang Yanlin, Zeng Yukun, Yu Lihua, Liu Ling, Zhang Yan, Yin Aihua
Prenatal Diagnosis Centre, Guangdong Women and Children Hospital, Guangzhou, China.
Maternal and Children Metabolic-Genetic Key Laboratory, Guangdong Women and Children Hospital, Guangzhou, China.
Front Pediatr. 2021 Aug 27;9:628238. doi: 10.3389/fped.2021.628238. eCollection 2021.
The long-term prognosis of a fetus with cardiac rhabdomyoma (CR) depends on the correlation with tuberous sclerosis complex (TSC). In recent years, the numerous variations of uncertain significance (VUS) of TSC genes produced by high-throughput sequencing have made counseling challenging, studies until now have tended to side-step the tricky topics. Here, we integrated detailed parental phenotype, echocardiography, neuro MRI, and genetic information to conduct a comprehensive evaluation of 61 CR fetuses. As a result, multiple CRs and cerebral lesions appeared in 90 and 80%, respectively of fetuses with pathogenic (P)/likely pathogenic (LP) TSC1/TSC2 variations. Overall, 85.7% of the live-born infants with P/LP presented with TSC-associated signs. While, 85.7% of VUS without nervous findings had good prognoses. Genetic evidence and cerebral MRI findings are the most sensitive index to assess long-term prognosis, which complement and confirm each other for a TSC diagnosis. In total, 68.9% of fetuses with CR could benefit from this multidisciplinary approach, which turned out to be potentially clinically actionable with precise clinical/genetic diagnosis or had a foreseeable outcome. Our practice provides a practical and feasible solution for perinatal management and prognostic guidance for fetuses with CR.
患有心脏横纹肌瘤(CR)的胎儿的长期预后取决于与结节性硬化症(TSC)的相关性。近年来,高通量测序产生的大量意义未明的TSC基因变异(VUS)给咨询带来了挑战,迄今为止的研究往往回避了这些棘手的话题。在此,我们整合了详细的父母表型、超声心动图、神经磁共振成像和基因信息,对61例CR胎儿进行了全面评估。结果,分别有90%和80%的携带致病性(P)/可能致病性(LP)TSC1/TSC2变异的胎儿出现多个CR和脑部病变。总体而言,85.7%的P/LP活产婴儿出现了与TSC相关的体征。而没有神经学表现的VUS中,85.7%预后良好。基因证据和脑部磁共振成像结果是评估长期预后最敏感的指标,它们相互补充并相互印证以进行TSC诊断。总的来说,68.9%的CR胎儿可从这种多学科方法中获益,这种方法通过精确的临床/基因诊断在临床上具有潜在的可操作性或具有可预见的结果。我们的实践为CR胎儿的围产期管理和预后指导提供了切实可行的解决方案。